72% of infection preventionists have single-site responsibilities

Nearly three quarters of infection preventionists (IP) had single-site responsibilities and dedicated more than 75 percent of their time to prevention and control, according to a study published May 31 in the American Journal of Infection Control.

Infection prevention and control (IPC) programs require staffing to maintain a high level of care. In this study, researchers examined the current IP staffing and IPC program resources in acute care hospitals to identify areas for improvement.

The study included data of 1,623 respondents from the 2015 MegaSurvey conducted by the Association of Professionals in Infection Prevention and Epidemiology. The differences facility and department characteristics by facility size were also analyzed.

 

Findings included:

  • 72 percent had single-site responsibilities.
  • IPs reported dedicating 76 to 100 percent of their job to IPC.
  • The overall medical IP staffing was 1.25 IPs per 100 patients.
  • 46 percent of IPs represented facilities with a daily inpatient census of less than 100, were the average number of IPs was 1.1.
  • IPs increased as the number of inpatients grew.
  • Researchers noted significant differences in IP staffing, responsibilities and support to IPC programs between smaller and larger hospitals.

“This study represents the current snapshot of IP staffing and IPC resources in acute care hospitals,” concluded first author Monika Pogorzelska-Maziarz, PhD, MPH, and colleagues. “Findings indicate important differences between large and small facilities in staffing and IPC resources. The field of infection prevention would benefit from a comprehensive assessment of IPC department staffing and resource needs.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.